Market Summary
USD36.03-0.27
Market Closed-0.74%
RPRX Stock Price
RPRX RSI Chart
RPRX Valuation
RPRX Price/Sales (Trailing)
RPRX Profitability
RPRX Fundamentals
RPRX Revenue
RPRX Earnings
Price Action
52 Week Range
32.6844.47
(Low)(High)
Last 7 days
1.7%
Last 30 days
1.2%
Last 90 days
-8.8%
Trailing 12 Months
-6.3%
RPRX Financial Health
RPRX Investor Care
Peers (Alternatives to Royalty Pharma)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AAPL | 2.6T | 387.5B | 13.48% | -5.13% | 27.45 | 6.74 | 2.44% | -5.35% |
MSFT | 2.1T | 204.1B | 17.07% | -5.81% | 31.83 | 10.52 | 10.38% | -5.25% |
GOOG | 1.3T | 282.8B | 14.90% | -25.53% | 22.28 | 4.72 | 9.78% | -21.12% |
AMZN | 1.1T | 514.0B | 12.06% | -36.63% | -388.65 | 2.06 | 9.40% | -108.16% |
| MID-CAP | ||||||||
NYMT | 3.6B | 258.4M | 0.64% | -20.32% | -12.17 | 14.06 | 24.91% | -254.56% |
JBLU | 2.4B | 9.2B | -11.76% | -51.30% | -6.58 | 0.26 | 51.67% | -98.90% |
| SMALL-CAP | ||||||||
PLAY | 1.8B | 1.7B | -7.84% | -25.07% | 14.36 | 1.02 | 61.79% | 371.82% |
TLRY | 1.6B | 602.5M | -7.75% | -62.41% | -2.73 | 2.62 | 18.18% | -18.59% |
BYND | 1.0B | 418.9M | -4.19% | -66.40% | -2.83 | 2.47 | -9.85% | -101.06% |
MFA | 1.0B | 482.4M | -5.07% | -32.73% | -4.36 | 2.09 | 33.15% | -170.42% |
CGC | 850.7M | 478.9M | -22.22% | -76.91% | -0.27 | 1.78 | -31.50% | -634.70% |
GPRO | 783.8M | 1.1B | -4.01% | -41.03% | 27.17 | 0.72 | -5.82% | -92.23% |
NKLA | 620.7M | 50.8M | -43.98% | -88.70% | -0.79 | 12.21 | 1229.98% | -13.59% |
INO | 204.5M | 10.3M | -33.87% | -77.16% | -0.73 | 19.92 | 478.23% | 7.85% |
Financials for Royalty Pharma
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | -0.4% | 2,237 | 2,247 | 2,259 | 2,278 | 2,289 |
| S&GA Expenses | 13.5% | 227 | 200 | 198 | 191 | 183 |
| R&D Expenses | -23.1% | 177 | 230 | 295 | 298 | 200 |
| Costs and Expenses | 48.0% | 1,930 | 1,304 | 1,205 | 857 | 859 |
| EBITDA | -61.4% | 418 | 1,082 | 1,080 | 1,386 | 1,407 |
| EBITDA Margin | -61.2% | 0.19* | 0.48* | 0.48* | 0.61* | 0.61* |
| Earnings Before Taxes | -74.3% | 230 | 894 | 895 | 1,210 | 1,241 |
| EBT Margin | -74.1% | 0.10* | 0.40* | 0.40* | 0.53* | 0.54* |
| Interest Expenses | 0.0% | 188 | 188 | 185 | 176 | 166 |
| Net Income | -91.5% | 43.00 | 507 | 466 | 602 | 620 |
| Net Income Margin | -91.5% | 0.02* | 0.23* | 0.21* | 0.26* | 0.27* |
| Free Cahsflow | 3.9% | 2,144 | 2,064 | 1,995 | 1,952 | 2,018 |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -4.9% | 16,813 | 17,673 | 17,740 | 17,379 | 17,516 |
| Current Assets | 9.1% | 2,555 | 2,342 | 3,504 | 2,982 | 2,878 |
| Cash Equivalents | 72.5% | 1,711 | 992 | 2,108 | 1,792 | 1,541 |
| Liabilities | 0.4% | 7,288 | 7,256 | 7,332 | 7,237 | 7,267 |
| Current Liabilities | 3.1% | 1,167 | 1,132 | 182 | 136 | 171 |
| Long Term Debt | 0.1% | 7,111 | 7,106 | 7,101 | 7,096 | - |
| LT Debt, Current | 0.1% | 998 | 997 | - | - | - |
| LT Debt, Non Current | 0.1% | 6,119 | 6,115 | 7,106 | 7,101 | 7,096 |
| Shareholder's Equity | -8.6% | 9,525 | 10,416 | 10,408 | 10,142 | 10,249 |
| Retained Earnings | -21.6% | 1,965 | 2,505 | 2,446 | 2,225 | 2,255 |
| Additional Paid-In Capital | 0.9% | 3,666 | 3,633 | 3,571 | 3,543 | 3,508 |
| Shares Outstanding | 0.7% | 439 | 436 | 434 | - | - |
| Minority Interest | -8.6% | 3,897 | 4,264 | 4,381 | 4,364 | 4,472 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 3.9% | 2,144 | 2,064 | 1,995 | 1,952 | 2,018 |
| Share Based Compensation | -3.2% | 3.00 | 3.00 | - | - | - |
| Cashflow From Investing | 48.4% | -1,029 | -1,995 | -1,416 | -1,259 | -1,870 |
| Cashflow From Financing | -7.7% | -944 | -877 | 387 | 391 | 385 |
| Buy Backs | - | 0.00 | - | - | - | - |
Risks for RPRX
What is the probability of a big loss on RPRX?
65.1%
Probability that Royalty Pharma stock will be more than 20% underwater in next one year
9.6%
Probability that Royalty Pharma stock will be more than 30% underwater in next one year.
0%
Probability that Royalty Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does RPRX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Royalty Pharma was unfortunately bought at previous high price.
Drawdowns
Returns for RPRX
Cumulative Returns on RPRX
Which funds bought or sold RPRX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-27 | Neo Ivy Capital Management | added | 10.39 | 22,000 | 277,000 | 0.19% |
2023-03-17 | American Portfolios Advisors | unchanged | - | -20.00 | 442 | -% |
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -13.54 | -133,192 | 756,808 | 0.02% |
2023-03-10 | BAILLIE GIFFORD & CO | reduced | -4.19 | -41,389,000 | 676,554,000 | 0.70% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 3.56 | 192,859 | 10,612,900 | 0.01% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -8.96 | -434,000 | 3,715,000 | 0.02% |
2023-03-01 | Regal Investment Advisors LLC | added | 4.95 | 7,054 | 226,054 | 0.02% |
2023-02-28 | Voya Investment Management LLC | added | 8.53 | 129,956 | 2,061,960 | -% |
2023-02-21 | MACQUARIE GROUP LTD | added | 30.31 | 79,493 | 364,493 | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 7,548 | 7,548 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Royalty Pharma News
Schedule 13G FIlings of Royalty Pharma
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | general atlantic, l.p. | 5.6% | 26,244,741 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.08% | 35,627,791 | SC 13G/A | |
| Feb 09, 2023 | adage capital partners gp, l.l.c. | 1.59% | 7e+06 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Apr 05, 2022 | giuliani mario germano | 2.9% | 12,604,660 | SC 13D/A | |
| Feb 10, 2022 | morgan stanley | 13.0% | 56,011,010 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 16, 2021 | general atlantic llc | 6.4% | 26,243,870 | SC 13G | |
| Feb 11, 2021 | adage capital partners gp, l.l.c. | 9.97% | 38,714,280 | SC 13G/A | |
| Feb 10, 2021 | morgan stanley | 11.9% | 46,144,883 | SC 13G/A |
RPRX Fair Value
Royalty Pharma fair value in different scenarios
The table shows the Fair Value estimates for Royalty Pharma for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | - - | - - | - - | - - |
| Current Inflation | 28.50 -20.90% | 36.65 1.72% | 44.42 23.29% | 53.61 48.79% | 64.89 80.10% |
| Very High Inflation | - - | - - | - - | - - | - - |
Historical Royalty Pharma Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Royalty Pharma
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 31, 2023 | 4 | Insider Trading | |
| Mar 31, 2023 | 4 | Insider Trading | |
| Mar 30, 2023 | 4 | Insider Trading | |
| Mar 30, 2023 | 4 | Insider Trading | |
| Mar 28, 2023 | 8-K | Current Report | |
| Mar 15, 2023 | 8-K | Current Report | |
| Feb 27, 2023 | 4 | Insider Trading | |
| Feb 24, 2023 | 4 | Insider Trading | |
| Feb 17, 2023 | 4 | Insider Trading | |
| Feb 17, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for RPRX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-30 | RIGGS RORY B | sold | -4,714,340 | 36.2575 | -130,024 | - |
2023-03-29 | Lloyd George W. | sold | -473,165 | 37.0268 | -12,779 | evp, investments & clo |
2023-03-29 | RIGGS RORY B | sold | -366,766 | 36.95 | -9,926 | - |
2023-03-28 | Lloyd George W. | sold | -3,706,130 | 37.0613 | -100,000 | evp, investments & clo |
2023-02-23 | Lloyd George W. | sold | -931,658 | 37.2663 | -25,000 | evp, investments & clo |
2023-02-22 | Urist Marshall | sold | -870,239 | 37.2965 | -23,333 | evp, research & investments |
2023-02-17 | Urist Marshall | acquired | - | - | 70,000 | evp, research & investments |
2023-02-17 | RIGGS RORY B | acquired | - | - | 1,500,000 | - |
2022-12-30 | Bassler Bonnie L | acquired | 37,494 | 39.7613 | 943 | - |
2022-12-30 | Fernandez Henry A | acquired | 37,494 | 39.7613 | 943 | - |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRX Income Statement
2022-12-31Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||||
|---|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |||
| Total income and other revenues | $ 2,237,215 | $ 2,289,463 | $ 2,122,353 | ||
| Operating expenses | |||||
| Provision for changes in expected cash flows from financial royalty assets | 904,244 | 452,842 | 230,839 | ||
| Research and development funding expense | 177,106 | 200,084 | 26,289 | ||
| Amortization of intangible assets | 5,670 | 22,996 | 23,058 | ||
| General and administrative expenses | 227,303 | 182,826 | 181,715 | ||
| Financial royalty asset impairment | 615,827 | 0 | 65,053 | ||
| Total operating expenses, net | 1,930,150 | 858,748 | 526,954 | ||
| Operating income | 307,065 | 1,430,715 | 1,595,399 | ||
| Other expense/(income) | |||||
| Equity in losses/(earnings) of equity method investees | 8,973 | 19,490 | (44,459) | ||
| Interest expense | 187,961 | 166,142 | 157,059 | ||
| (Gains)/losses on derivative financial instruments | (96,610) | 21,532 | 42,076 | ||
| Losses/(gains) on equity securities | 33,442 | 48,066 | (247,073) | ||
| Losses/(gains) on available for sale debt securities | 6,815 | (17,859) | (18,600) | ||
| Interest income | (78,335) | (53,535) | (28,379) | ||
| Other non-operating expense, net | 14,755 | 5,678 | 32,821 | ||
| Total other expenses/(income), net | 77,001 | 189,514 | (106,555) | ||
| Consolidated net income before tax | 230,064 | 1,241,201 | 1,701,954 | ||
| Income tax expense | 0 | 0 | 0 | ||
| Consolidated net income | 230,064 | 1,241,201 | 1,701,954 | ||
| Net income attributable to non-controlling interests | 187,232 | 621,473 | 726,914 | ||
| Net income attributable to Royalty Pharma plc | $ 42,832 | $ 619,728 | $ 975,040 | ||
| Earnings per Class A ordinary share | |||||
| Basic (in dollars per share) | [1] | $ 0.10 | $ 1.49 | $ 1.32 | |
| Diluted (in dollars per share) | [1] | $ 0.10 | $ 1.49 | $ 1.32 | |
| Weighted average Class A ordinary shares outstanding | |||||
| Basic (in shares) | [1] | 437,963 | 414,794 | 375,444 | |
| Diluted (in shares) | [1] | 437,972 | 414,802 | 375,455 | |
| Income from financial royalty assets | |||||
| Total income and other revenues | $ 2,125,096 | $ 2,065,083 | $ 1,959,975 | ||
| Revenue from intangible royalty assets | |||||
| Total income and other revenues | 37,484 | 171,248 | 143,382 | ||
| Other royalty income | |||||
| Total income and other revenues | $ 74,635 | $ 53,132 | $ 18,996 | ||
| |||||
RPRX Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 1,710,751 | $ 1,541,048 |
| Marketable securities | 24,421 | 581,872 |
| Financial royalty assets | 691,319 | 614,351 |
| Accrued royalty receivable | 16,830 | 53,286 |
| Available for sale debt securities | 1,300 | 66,000 |
| Other royalty income receivable | 19,767 | 15,023 |
| Other current assets | 90,520 | 6,631 |
| Total current assets | 2,554,908 | 2,878,211 |
| Financial royalty assets, net | 13,493,106 | 13,718,245 |
| Intangible royalty assets, net | 0 | 5,670 |
| Equity securities | 112,348 | 269,800 |
| Available for sale debt securities | 226,300 | 204,400 |
| Equity method investments | 397,175 | 435,394 |
| Other assets | 29,629 | 4,145 |
| Total assets | 16,813,466 | 17,515,865 |
| Current liabilities | ||
| Distributions payable to legacy non-controlling interests | 94,803 | 107,934 |
| Accounts payable and accrued expenses | 7,906 | 5,620 |
| Interest payable | 54,162 | 57,696 |
| Current portion of long-term debt | 997,512 | 0 |
| Other current liabilities | 12,400 | 0 |
| Total current liabilities | 1,166,783 | 171,250 |
| Long-term debt | 6,118,810 | 7,096,070 |
| Other liabilities | 2,500 | 0 |
| Total liabilities | 7,288,093 | 7,267,320 |
| Commitments and contingencies | ||
| Shareholders’ equity | ||
| Deferred shares, $0.000001 par value, 371,325 and 361,170 issued and outstanding, respectively | 0 | 0 |
| Additional paid-in capital | 3,666,160 | 3,507,533 |
| Retained earnings | 1,964,689 | 2,255,179 |
| Non-controlling interests | 3,897,223 | 4,471,951 |
| Accumulated other comprehensive income | 0 | 16,491 |
| Treasury interests | (2,806) | (2,715) |
| Total shareholders’ equity | 9,525,373 | 10,248,545 |
| Total liabilities and shareholders’ equity | 16,813,466 | 17,515,865 |
| Class A Ordinary Shares | ||
| Shareholders’ equity | ||
| Common stock | 44 | 43 |
| Class B Ordinary Shares | ||
| Shareholders’ equity | ||
| Common stock | 0 | 0 |
| Class R Redeemable Shares | ||
| Shareholders’ equity | ||
| Common stock | $ 63 | $ 63 |